Experimental Hematology
Volume 36, Issue 1 , Pages 9-16 , January 2008

Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics

  • Maxim Yankelevich

      Affiliations

    • Texas Children's Cancer Center, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Tex., USA
    • Corresponding Author InformationOffprint requests to: Maxim Yankelevich M.D., Institute for Pediatric Oncology and Hematology, N.N Blokhin Russian Cancer Research Center, 24 Kashirskoe shosse, Moscow, 115478, Russia
    • ,
  • Margaret A. Goodell

      Affiliations

    • Texas Children's Cancer Center, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Tex., USA
    • ,
  • Joseph Kaplan

      Affiliations

    • Department of Pediatrics, Wayne State University Medical School, Detroit, Mich., USA

Received 1 November 2006 ,Revised 7 July 2007 ,Accepted 13 August 2007.

References 

  1. Rahiala J, Perkkio M, Riikonen P. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (Filgrastim) in children with cancer. Med Pediatr Oncol. 1999;32:326–330
  2. Elonen E, Jantunen E, Koistinen P, et al. G-CSF (lenograstim) following chemotherapy in the induction treatment of acute lymphoblastic leukemia (ALL) in adults. A randomized study between early and delayed start. Blood. 1996;88(Suppl 1):213a
  3. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci U S A. 1997;94:1908–1913
  4. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104:65–72
  5. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151:2399–2408
  6. Hestdal K, Ruscetti FW, Ihle JN, et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol. 1991;147:22–28
  7. Krause DS, Takahiko I, Fackler MJ, et al. Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood. 1994;84:691–701
  8. Okuno Y, Iwasaki H, Huettner CS, et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002;99:6246–6251
  9. Ebihara Y, Xu MJ, Manabe A, et al. Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34+ cells. Br J Haematol. 2000;109:153–161
  10. Tassi C, Tazzari PL, Bonifazi F, et al. Short- and long-term hematological surveillance of healthy donors of allogeneic peripheral hematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant. 2005;36:289–294
  11. Timmer-Bonte JN, de Mulder PH, Peer PG, et al. Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during dose-dense chemotherapy. Breast Cancer Res Treat. 2005;93:117–123
  12. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687–694
  13. Stewart FM, Temeles D, Lowry , Thraves T, Grosh WW, Quesenberry PJ. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood. 1993;181:2283–2289
  14. Riccardi A, Danova M, Paccagnella A, et al. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with GM-CSF. Ann Hematol. 1993;66:185–193
  15. Ostby I, Kvalheim G, Rusten LS, Grottum P. Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment. J Theor Biol. 2004;231:69–83
  16. Dolgopolov I, Andreeva L, Yankelevich M, et al. Delayed Introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases. Am J Hematol. 2003;73:225–229
  17. Gomez AT, Jimenez MA, Alvarez MA, et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol. 1995;71:65–70
  18. Hofmann WK, Seipelt G, Langenhan S, et al. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2002;81:570–574
  19. Weiser MA, O'Brien S, Thomas DA, et al. Comparison of two different schedules of granulocyte colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristin, and dexamethasone) regimen. Cancer. 2002;94:285–291

PII: S0301-472X(07)00528-0

doi: 10.1016/j.exphem.2007.08.019

Experimental Hematology
Volume 36, Issue 1 , Pages 9-16 , January 2008

Article Tools

* Image Usage & Resolution